Michael Grippo - Catalent Insider

Insider

Michael Grippo is Senior Vice President - Strategy and Corporate Development of Catalent since 2019.
Age 55
Tenure 6 years
Phone732 537 6200
Webhttps://www.catalent.com

Michael Grippo Latest Insider Activity

Tracking and analyzing the buying and selling activities of Michael Grippo against Catalent stock is an integral part of due diligence when investing in Catalent. Michael Grippo insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Catalent Management Efficiency

Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.
Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Flavia PeaseCharles River Laboratories
51
Simon MayBio Rad Laboratories
52
John CFATeleflex Incorporated
N/A
Jay WhiteTeleflex Incorporated
51
Molly JosephWest Pharmaceutical Services
46
Dara WrightBio Rad Laboratories
48
Costa PanagosIQVIA Holdings
N/A
Daniel LogueTeleflex Incorporated
50
Robert SeguraWest Pharmaceutical Services
N/A
Richard LuzziWest Pharmaceutical Services
72
James WintersTeleflex Incorporated
48
Victoria CreamerCharles River Laboratories
55
Andrew MarkwickIQVIA Holdings
N/A
Matt TomkinTeleflex Incorporated
N/A
Kimberly MacKayWest Pharmaceutical Services
58
Jeffrey SpaederIQVIA Holdings
N/A
Trudy SteinIQVIA Holdings
N/A
Cindy ReissClarkWest Pharmaceutical Services
50
Ajit RamalingamBio Rad Laboratories
51
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey. Catalent operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 19000 people. Catalent (CTLT) is traded on New York Stock Exchange in USA and employs 17,000 people.

Management Performance

Catalent Leadership Team

Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Castellano, VP of Fin. and Investor Relations and Treasurer
Paul Surdez, Vice Relations
Joseph JD, General VP
Tom PEng, President Delivery
Trish Hunt, President Health
Peter Zippelius, Independent Director
David McErlane, Group Segment
Steven Fasman, Senior Vice President General Counsel and Corporate Secretary
Michael Hatzfeld, VP Officer
Kay Schmidt, Senior Vice President - Technical Operations
Karen Santiago, VP Office
Jonathan Arnold, President - Oral & Specialty Delivery
Ricky Hopson, Division President
John MBA, Executive Board
John Chiminski, Chairman of the Board, Chief Executive Officer
Donald Morel, Independent Director
John Greisch, Independent Director
Gregory Lucier, Independent Director
Rolf Classon, Independent Director
Michael Barber, Independent Director
Steven Esq, Corp VP
Karen Flynn, President - Biologics and Chief Commercial Officer
Michael Grippo, Senior Vice President - Strategy and Corporate Development
Matti Masanovich, Senior CFO
Julien Meissonnier, VP Officer
Christa Kreuzburg, Independent Director
Lisa Evoli, Senior Officer
Madhavan Balachandran, Independent Director
J Carroll, Independent Director
Scott Gunther, Senior Vice President - Quality & Regulatory Affairs
Wetteny Joseph, Chief Financial Officer, Senior Vice President
Alessandro Maselli, Senior Vice President - Global Operations
Dejan Lamesic, Head Development
Ricci Whitlow, President - Clinical Supply Services
Charles Lickfold, Senior Vice President, Chief Information Officer
Aristippos Gennadios, President - Softgel & Oral Technologies
Ricardo Pravda, Chief Human Resource Officer, Senior Vice President
Jack Stahl, Lead Independent Director
Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy
Rosemary Crane, Independent Director

Catalent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.

Other Consideration for investing in Catalent Stock

If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals